DARZALEX® + Pomalyst® (pomalidomide) + dexamethasone
Nearly 60% of patients responded to DARZALEX® (daratumumab) + Pd1*
PR=partial response; VGPR=very good partial response; CR=complete response; sCR=stringent complete response.
*Efficacy results were based on ORR as determined by an Independent Review Committee assessment using International Myeloma Working Group (IMWG) criteria.1
Median time to response
- With DARZALEX® + Pd (n=61), median time to response was 1 month (range: 0.9 to 2.8 months), median time to VGPR or better was 1.9 months (range: 0.9 to 8.8 months), and median time to CR or better was 5.4 months (range: 2.8 to 9.9 months)1,2
Median duration of response with DARZALEX® + Pd was 13.6 months
(range: 0.9+ to 14.6+ months)1